Works matching IS 01615505 AND DT 2022 AND VI 63 AND IP 1

Results: 7

SNMMI Newsline.

Published in:: Journal of Nuclear Medicine, 2022, v. 63, n. 1, p. 11N
Publication type:: Article

Advancing Nuclear Medicine in Australia over 3 Decades: A Conversation Between Rodney Hicks, Johannes Czernin, and Ken Herrmann.

Published in:

Journal of Nuclear Medicine, 2022, v. 63, n. 1, p. 1, doi. 10.2967/jnumed.121.263338

By:

Hicks, Rodney;
Czernin, Johannes;
Herrmann, Ken

Publication type:

Article

Administration Routes for SSTR- / PSMA- and FAP-directed Theranostic Radioligands in Mice.

Published in:

Journal of Nuclear Medicine, 2022, v. 63, n. 1, p. 1, doi. 10.2967/jnumed.121.263453

By:

Klose, Jasmin M.;
Wosniack, Jasmin;
Iking, Janette;
Staniszewska, Magdalena;
Zarrad, Fadi;
Trajkovic-Arsic, Marija;
Herrmann, Ken;
Costa, Pedro Fragoso;
Lueckerath, Katharina;
Fendler, Wolfgang P.

Publication type:

Article

Utility of 18F-rhPSMA-7.3 positron emission tomography for imaging of primary prostate cancer and pre-operative efficacy in N-staging of unfavorable intermediate to very high-risk patients validated by histopathology.

Published in:

Journal of Nuclear Medicine, 2022, v. 63, n. 1, p. 1, doi. 10.2967/jnumed.121.263440

By:

Langbein, Thomas;
Hui Wang;
Rauscher, Isabel;
Kroenke, Markus;
Knorr, Karina;
Wurzer, Alexander;
Schwamborn, Kristina;
Maurer, Tobias;
Horn, Thomas;
Haller, Bernhard;
Wester, Hans-Jürgen;
Eiber, Matthias

Publication type:

Article

Targeted Alpha-Emitter Therapy With 212Pb-DOTAMTATE for the Treatment of Metastatic SSTR-Expressing Neuroendocrine Tumors: First-in-Human, Dose-Escalation Clinical Trial.

Published in:

Journal of Nuclear Medicine, 2022, v. 63, n. 1, p. 1, doi. 10.2967/jnumed.121.263230

By:

Delpassand, Ebrahim S.;
Tworowska, Izabela;
Esfandiari, Rouzbeh;
Torgue, Julien;
Hurt, Jason;
Shafie, Afshin;
Núñez, Rodolfo

Publication type:

Article

The impact of semi-automatic segmentation methods on metabolic tumor volume, intensity and dissemination radiomics in 18F-FDG PET scans of patients with classical Hodgkin lymphoma.

Published in:

Journal of Nuclear Medicine, 2022, v. 63, n. 1, p. 1, doi. 10.2967/jnumed.121.263067

By:

Driessen, Julia;
Zwezerijnen, Gerben J. C.;
Schöder, Heiko;
Drees, Esther E. E.;
Kersten, Marie José;
Moskowitz, Alison J.;
Moskowitz, Craig H.;
Eertink, Jakoba J.;
de Vet, Henrica C. W.;
Hoekstra, Otto S.;
Zijlstra, Josée M.;
Boellaard, Ronald

Publication type:

Article

CD8-targeted PET Imaging of Tumor Infiltrating T cells in Patients with Cancer: A Phase I First-in-Human Study of 89Zr-Df-IAB22M2C, a Radiolabeled anti-CD8 Minibody.

Published in:

Journal of Nuclear Medicine, 2022, v. 63, n. 1, p. 1, doi. 10.2967/jnumed.121.262485

By:

Farwell, Michael D.;
Gamache, Raymond F.;
Babazada, Hasan;
Hellmann, Matthew D.;
Harding, James J.;
Korn, Ron;
Mascioni, Alessandro;
Le, William;
Wilson, Ian;
Gordon, Michael S.;
Wu, Anna M.;
Ulaner, Gary A.;
Wolchok, Jedd D.;
Postow, Michael A.;
Pandit-Taskar, Neeta

Publication type:

Article

Works matching IS 01615505 AND DT 2022 AND VI 63 AND IP 1

SNMMI Newsline.

Advancing Nuclear Medicine in Australia over 3 Decades: A Conversation Between Rodney Hicks, Johannes Czernin, and Ken Herrmann.

Administration Routes for SSTR- / PSMA- and FAP-directed Theranostic Radioligands in Mice.

Utility of <sup>18</sup>F-rhPSMA-7.3 positron emission tomography for imaging of primary prostate cancer and pre-operative efficacy in N-staging of unfavorable intermediate to very high-risk patients validated by histopathology.

Targeted Alpha-Emitter Therapy With <sup>212</sup>Pb-DOTAMTATE for the Treatment of Metastatic SSTR-Expressing Neuroendocrine Tumors: First-in-Human, Dose-Escalation Clinical Trial.

The impact of semi-automatic segmentation methods on metabolic tumor volume, intensity and dissemination radiomics in <sup>18</sup>F-FDG PET scans of patients with classical Hodgkin lymphoma.

CD8-targeted PET Imaging of Tumor Infiltrating T cells in Patients with Cancer: A Phase I First-in-Human Study of <sup>89</sup>Zr-Df-IAB22M2C, a Radiolabeled anti-CD8 Minibody.